1. Long-term Low-Molecular-Weight Heparin and the Post-Thrombotic Syndrome: A Systematic Review 
Russell D. Hull, MBBS, MSc, Jane Liang, MSc, Grace Townshend, MSc 
The American Journal of Medicine 
Volume 124, Issue 8, Pages (August 2011)
DOI: /j.amjmed
Copyright © 2011 Elsevier Inc. Terms and Conditions

2. Figure 1
Risk ratios for the (A) presence of venous ulcers and (B) absence of complete recanalization of thrombosed veins or complete lysis of thrombus, after treatment with long-term low-molecular-weight heparin or oral anticoagulation. A ratio of < 1 favors tinzaparin. Both were calculated using a fixed-effect model. For ulcers: Daskalopoulos et al's trial:24 6-mo therapy with tinzaparin and follow-up at 1 y; Hull et al's study:11 3-mo therapy with tinzaparin and follow-up at 3 mo. For recanalization: Values are those reported for follow-up at 6 mo for Romera et al19 and 3 mo for all the other studies. For López-Beret et al,26 values reported for the popliteal vein were used. Values for the common and superficial femoral veins would have favored low-molecular-weight heparin to an even greater extent (Table 3). CI = confidence interval; LMWH = low-molecular-weight heparin; OA = oral anticoagulant.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © 2011 Elsevier Inc. Terms and Conditions